Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | TSPO | P30536 | 1/20 | 0.57 |
| ▸ | MAPT | P10636 | 2/20 | 0.49 |
| ▸ | TP53 | P04637 | 3/20 | 0.47 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.42 |
| ▸ | GAA | P10253 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3933595 | 0.90 | TSPO (0.59) | TSPOMAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL5785148 | 0.90 | TSPO (0.59) | TSPOMAPTTP53POLB | |
| Hydrochloric Acid SCHEMBL3927977 | 0.89 | TSPO (0.58) | TSPOMAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL7003823 | 0.89 | TSPO (0.71) | TSPOMAPTTP53POLBSMN1; SMN2 | |
| Hydrochloric Acid SCHEMBL3920180 | 0.89 | TSPO (0.58) | TSPOMAPTTP53POLB | |
| SCHEMBL7626011 | 0.88 | TSPO (0.64) | TSPOMAPTTP53SMN1; SMN2 | |
| SCHEMBL3931680 | 0.86 | TSPO (0.54) | TSPOMAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL3922978 | 0.85 | TSPO (0.56) | TSPOMAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL3922429 | 0.85 | TSPO (0.54) | TSPOMAPTTP53POLBSMN1; SMN2 | |
| SCHEMBL3932372 | 0.84 | TSPO (0.50) | TSPOMAPTTP53POLBSMN1; SMN2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 14 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20090275576-A1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-11-05 | — | — | US | claimed |
| US-7569567-B2 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide derivatives, their preparation and therapeutic use | SANOFI-AVENTIS (FR) | 2009-08-04 | — | — | US | claimed |
| US-20080249098-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide Derivatives, Their Preparation and Therapeutic Use | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | US | claimed |
| US-20060241116-A1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2006-10-26 | — | — | US | claimed |
| US-7109194-B2 | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino[4, 5-b]indole-1-carboxamide derivatives their preparations and therapeutic use | SANOFI-AVENTIS (FR) | 2006-09-19 | — | — | US | claimed |
| US-20050096321-A1 | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino[4, 5-b]indole-1-carboxamide derivatives their preparations and therapeutic use | SANOFI (FR) | 2005-05-05 | — | — | US | claimed |
| US-20090275576-A1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2009-11-05 | — | — | US | disclosed |
| US-7569567-B2 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide derivatives, their preparation and therapeutic use | SANOFI-AVENTIS (FR) | 2009-08-04 | — | — | US | disclosed |
| US-20080249098-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide Derivatives, Their Preparation and Therapeutic Use | SANOFI-AVENTIS (FR) | 2008-10-09 | — | — | US | disclosed |
| US-7402682-B2 | 3-heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide derivatives, their preparation and therapeutic use | SANOFI-AVENTIS (FR) | 2008-07-22 | — | — | US | disclosed |
| EP-1458721-B1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO [4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI AVENTIS (FR) | 2006-11-22 | — | — | EP | disclosed |
| US-20060241116-A1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | SANOFI-AVENTIS (FR) | 2006-10-26 | — | — | US | disclosed |
| US-7109194-B2 | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino[4, 5-b]indole-1-carboxamide derivatives their preparations and therapeutic use | SANOFI-AVENTIS (FR) | 2006-09-19 | — | — | US | disclosed |
| US-20050096321-A1 | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino[4, 5-b]indole-1-carboxamide derivatives their preparations and therapeutic use | SANOFI (FR) | 2005-05-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060241116-A1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | HTR3C, TPH1, IDO1 | TSPO 1826/4885MAPT 3189/4885TP53 1779/4885 |
| US-20050096321-A1 | 3-heteroaryl-3, 5-dihydro-4-oxo-4H-pyridazino[4, 5-b]indole-1-carboxamide derivatives their preparations and therapeutic use | HTR3C, CYP3A43, IDO1 | TSPO 1918/4885MAPT 3630/4885TP53 1643/4885 |
| US-20090275576-A1 | 3-HETEROARYL-3,5-DIHYDRO-4-OXO-4H-PYRIDAZINO[4,5-B]INDOLE-1-CARBOXAMIDE DERIVATIVES, THEIR PREPARATION AND THERAPEUTIC USE | HTR3C, TPH1, IDO1 | TSPO 1826/4885MAPT 3189/4885TP53 1779/4885 |
| US-20080249098-A1 | 3-Heteroaryl-3,5-dihydro-4-oxo-4H-pyridazino[4,5-B]indole-1-carboxamide Derivatives, Their Preparation and Therapeutic Use | HTR3C, TPH1, IDO1 | TSPO 1826/4885MAPT 3189/4885TP53 1779/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.